Initiate IV unfractionated heparin immediately for suspected PE, despite the sacral pressure ulcer and septic shock
This 75-year-old patient presents with a life-threatening combination requiring urgent anticoagulation. The mortality risk from untreated pulmonary embolism far exceeds the bleeding risk from a sacral pressure ulcer, making therapeutic anticoagulation the priority.
Clinical Reasoning
Why Anticoagulation is Critical
For suspected PE with hemodynamic instability (septic shock + hypoxia):
- The 2019 ESC guidelines recommend immediate UFH with weight-adjusted bolus for high-risk PE 1
- The FDA label explicitly indicates UFH for "prophylaxis and treatment of venous thrombosis and pulmonary embolism" 2
- British Thoracic Society guidelines specify starting IV heparin for suspected PE even before diagnostic confirmation 3
The patient has multiple major PE risk factors:
- Immobilization (bedridden)
- Major medical illness (septic shock)
- Age 75 years
- Hypoxia with suspected PE
Addressing the Bleeding Concern
The sacral pressure ulcer is NOT an absolute contraindication:
- Absolute contraindications per Surviving Sepsis guidelines include: active bleeding, severe coagulopathy, thrombocytopenia, recent intracerebral hemorrhage 4
- A sacral pressure ulcer, while a relative concern, does not constitute active major hemorrhage
- The risk-benefit calculation heavily favors anticoagulation when PE is suspected with hemodynamic compromise
Septic Shock Context
Anticoagulation in septic shock has additional benefits:
- The Surviving Sepsis Campaign 2016 guidelines recommend pharmacologic VTE prophylaxis in sepsis patients 4
- Recent evidence suggests early UFH in septic shock may reduce 28-day mortality, particularly in severely ill patients (HR 0.70,95% CI 0.54-0.92) 5
- UFH possesses anti-inflammatory properties beyond anticoagulation that may benefit sepsis outcomes 6
Practical Implementation
Dosing Protocol (from FDA label and BTS guidelines) 2, 3:
Initial bolus: 80 IU/kg IV (or 5,000-10,000 units standard dose)
Continuous infusion: 18 IU/kg/hour (or 1,300 IU/hour standard, approximately 20,000-40,000 units/24 hours)
Target aPTT: 1.5-2.5 times control (45-75 seconds)
Monitoring schedule:
- Baseline: aPTT, INR, platelet count, hemoglobin
- Check aPTT 4-6 hours after bolus
- Check aPTT 6-10 hours after any dose adjustment
- Once therapeutic: daily aPTT
- Monitor platelets, hemoglobin, and occult blood throughout therapy
Critical Monitoring for the Sacral Ulcer
- Inspect wound daily for increased bleeding
- Monitor hemoglobin every 12-24 hours initially
- Apply local pressure dressings if minor oozing occurs
- Do NOT stop anticoagulation for minor wound oozing—adjust local wound care instead
When to Reconsider
Stop UFH only if:
- Frank hemorrhage from the ulcer requiring transfusion
- Platelet count drops suggesting HIT (typically day 5-10)
- Hemodynamic instability worsens due to bleeding (not PE progression)
Why UFH Over LMWH in This Case
While Surviving Sepsis guidelines prefer LMWH for VTE prophylaxis 4, UFH is superior for suspected PE with shock:
- Shorter half-life allows rapid reversal if bleeding occurs
- More titratable in hemodynamically unstable patients
- Renal function may be impaired in septic shock (LMWH contraindicated if CrCl <30 mL/min) 4
- ESC guidelines specifically recommend UFH for high-risk PE 1
Common Pitfalls to Avoid
- Delaying anticoagulation while awaiting imaging confirmation—start immediately if clinical suspicion is high 3, 1
- Using prophylactic rather than therapeutic doses—this patient needs full anticoagulation for suspected PE
- Stopping heparin prematurely for minor wound oozing—manage locally unless major hemorrhage occurs
- Forgetting to monitor platelets—HIT risk exists, check platelets at baseline and every 2-3 days
The presence of a sacral pressure ulcer does not justify withholding life-saving anticoagulation for suspected PE in a hemodynamically compromised patient. The mortality benefit of treating PE vastly outweighs the manageable bleeding risk from a pressure ulcer.